Document:

<PAGE>   1
                                                                     EXHIBIT 4.2

                            STOCK PURCHASE AGREEMENT

Amylin Pharmaceuticals, Inc.
9373 Towne Centre Drive
San Diego, California 92121

The undersigned (the "Investor"), hereby confirms its agreement with you as
follows:

1. This Stock Purchase Agreement (the "Agreement") is made as of the date set
forth below between Amylin Pharmaceuticals, Inc., a Delaware corporation (the
"Company"), and the Investor.

2. The Company has authorized the sale and issuance of up to
_______________________ shares (the "Shares") of common stock of the Company,
$.001 par value per share (the "Common Stock"), subject to adjustment by the
Company's Board of Directors, to certain investors in a private placement (the
"Offering").

3. The Company and the Investor agree that the Investor will purchase from the
Company and the Company will issue and sell to the Investor ____________ shares,
for a purchase price of $_________________ per share, or an aggregate purchase
price of $____________________, pursuant to the Terms and Conditions for
Purchase of Shares attached hereto as Annex I and incorporated herein by this
reference as if fully set forth herein. Unless otherwise requested by the
Investor, certificates representing the Shares purchased by the Investor will be
registered in the Investor's name and address as set forth below.

4. The Investor represents that, except as set forth below, (a) it has had no
position, office or other material relationship within the past three years with
the Company or its affiliates, (b) neither it, nor any group of which it is a
member or to which it is related, beneficially owns (including the right to
acquire or vote) any securities of the Company and (c) it has no direct or
indirect affiliation or association with any NASD member. Exceptions:

________________________________________________________________________________
                (If no exceptions, write "none." If left blank,
                     response will be deemed to be "none.")

Please confirm that the foregoing correctly sets forth the agreement between us
by signing in the space provided below for that purpose.

                                        DATED AS OF:                     , 2000
                                                      -------------------

                                        ---------------------------------------
                                        "INVESTOR"

                                        By:
                                           -------------------------------------
                                        Print Name:
                                                   -----------------------------
                                        Title:
                                              ----------------------------------
                                        Address:
                                                --------------------------------

                                        ----------------------------------------

AGREED AND ACCEPTED:
AMYLIN PHARMACEUTICALS, INC.

By:
   -------------------------------------
Title:
      ----------------------------------

<PAGE>   2

                                     ANNEX I

                   TERMS AND CONDITIONS FOR PURCHASE OF SHARES

        1. AUTHORIZATION AND SALE OF THE SHARES. Subject to the terms and
conditions of this Agreement, the Company has authorized the sale of the Shares.

        2. AGREEMENT TO SELL AND PURCHASE THE SHARES; SUBSCRIPTION DATE.

               2.1 At the Closing (as defined in Section 3), the Company will
sell to the Investor, and the Investor will purchase from the Company, upon the
terms and conditions hereinafter set forth, the number of Shares set forth on
the signature page to which these Terms and Conditions for Purchase of Shares
are attached as Annex I (the "Signature Page") at the purchase price set forth
on such Signature Page.

               2.2 The Company proposes to enter into this same form of Stock
Purchase Agreement with certain other investors (the "Other Investors") and
expects to complete sales of Shares to them. (The Investor and the Other
Investors are hereinafter sometimes collectively referred to as the "Investors,"
and this Agreement and the Stock Purchase Agreements executed by the Other
Investors are hereinafter sometimes collectively referred to as the
"Agreements.") The Company will accept executed Agreements from Investors for
the purchase of Shares commencing upon the date on which the Company provides
the Investors with the proposed purchase price per Share and concluding upon the
date (the "Subscription Date") on which the Company has (i) executed Agreements
with Investors for the purchase of Shares in the amount of at least $40,000,000
in the aggregate and (ii) notified Chase Securities Inc., Prudential Vector
Healthcare Group and Warburg Dillon Read LLC (in their capacities as Placement
Agents for the Shares, the "Placement Agents") in writing that it is no longer
accepting Agreements from Investors for the purchase of Shares.

               2.3 Investor acknowledges that the Company intends to pay the
Placement Agents a fee in respect of the sale of Shares to the Investor.

        3. DELIVERY OF THE SHARES AT CLOSING. The completion of the purchase and
sale of the Shares (the "Closing") shall occur at a place and time (the "Closing
Date") to be specified by the Company and the Placement Agents, not later than
four (4) complete trading days following the Subscription Date unless otherwise
extended by the Company, and of which the Investors will be notified in advance
by the Placement Agents. At the Closing, (i) the Company shall deliver to the
Investor one or more stock certificates representing the number of Shares set
forth on the signature page hereto, each such certificate to be registered in
the name of the Investor or, if so indicated on the Stock Certificate
Questionnaire attached hereto as Exhibit A, in the name of a nominee designated
by the Investor and (ii) the Investor shall deliver immediately available funds
in the amount of the aggregate purchase price for the Shares by wire transfer to
an account designated by the Placement Agents.

        The Company's obligation to issue the Shares to the Investor shall be
subject to the following conditions, any one or more of which may be waived by
the Company: (a) receipt by the Company of the purchase price for the Shares
being purchased hereunder as set forth on the

                                       1.
<PAGE>   3

Signature Page hereto; (b) completion of purchases and sales under the
Agreements with the Other Investors; and (c) the accuracy of the representations
and warranties made by the Investors and the fulfillment of those undertakings
of the Investors to be fulfilled prior to the Closing.

        The Investor's obligation to purchase the Shares shall be subject to the
following conditions, any one or more of which may be waived by the Investor:
(a) Investors shall have executed Agreements for the purchase of Shares in the
amount of at least $40,000,000 in the aggregate; (b) the accuracy of the
Company's representations and warranties contained in this Agreement at the
Closing; and (c) the satisfaction of all of the conditions set forth in the
Placement Agency Agreement between the Company and the Placement Agents. Subject
to clause (a) above, the Investor's obligations are expressly not conditioned on
the purchase by any or all of the other Investors of the Shares that they have
agreed to purchase from the Company.

        4. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. Except as
otherwise described in the Company's regular reports on Form 10-Q and 10-K and
the Company's Registration Statement on Form S-3 (Registration No. 333-87033) as
filed by the Company with the Securities and Exchange Commission in 1999 (the
"SEC Documents") and provided to the Investor, in the Company's press releases
since September 30, 1999 provided to the Investor, and in the other proprietary
information disclosed by the Company to the Investor in contemplation of this
offering (including the documents incorporated by reference therein, the
"Company Information"), which qualifies the following representations and
warranties in their entirety, the Company hereby represents and warrants to, and
covenants with, the Investor, as follows:

               4.1 ORGANIZATION. The Company is duly incorporated and validly
existing in good standing under the laws of the jurisdiction of its
organization. The Company has full power and authority to own, operate and
occupy its properties and to conduct its business as presently conducted and is
registered or qualified to do business and in good standing in each jurisdiction
in which it owns or leases property or transacts business and where the failure
to be so qualified would have a material adverse effect upon the business,
financial condition, properties or operations of the Company ("Material Adverse
Effect"), and no proceeding has been instituted in any such jurisdiction
revoking, limiting or curtailing, or seeking to revoke, limit or curtail, such
power and authority or qualification.

               4.2 DUE AUTHORIZATION. The Company has all requisite power and
authority to execute, deliver and perform its obligations under the Agreements,
and the Agreements have been duly authorized and validly executed and delivered
by the Company and constitute legal, valid and binding agreements of the Company
enforceable against the Company in accordance with their terms, except as rights
to indemnity and contribution may be limited by state or federal securities laws
or the public policy underlying such laws, except as enforceability may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting creditors' and contracting parties' rights generally and
except as enforceability may be subject to general principles of equity
(regardless of whether such enforceability is considered in a proceeding in
equity or at law).

               4.3 NON-CONTRAVENTION. The execution and delivery of the
Agreements, the issuance and sale of the Shares to be sold by the Company under
the Agreements, the fulfillment

                                       2.
<PAGE>   4

of the terms of the Agreements and the consummation of the transactions
contemplated thereby will not (A) conflict with or constitute a violation of, or
default (with the passage of time or otherwise) under, (i) any material bond,
debenture, note or other evidence of indebtedness, or any material lease,
contract, indenture, mortgage, deed of trust, loan agreement, joint venture or
other agreement or instrument to which the Company is a party or by which it or
its property is bound, where such conflict, violation or default is likely to,
individually or in the aggregate, result in a Material Adverse Effect, (ii) the
charter, by-laws or other organizational documents of the Company, or (iii) any
law, administrative regulation, ordinance or order of any court or governmental
agency, arbitration panel or authority binding upon the Company or its property,
where such conflict, violation or default is likely to, individually or in the
aggregate, result in a Material Adverse Effect, or (B) result in the creation or
imposition of any lien, encumbrance, claim, security interest or restriction
whatsoever upon any of the material properties or assets of the Company or an
acceleration of indebtedness pursuant to any obligation, agreement or condition
contained in any material bond, debenture, note or any other evidence of
indebtedness or any material indenture, mortgage, deed of trust or any other
agreement or instrument to which the Company is a party or by which it is bound
or to which any of the property or assets of the Company is subject. No consent,
approval, authorization or other order of, or registration, qualification or
filing with, any regulatory body, administrative agency, or other governmental
body in the United States is required for the execution and delivery of the
Agreements and the valid issuance and sale of the Shares to be sold pursuant to
the Agreements, other than such as have been made or obtained, and except for
any securities filings required to be made under federal or state securities
laws.

               4.4 CAPITALIZATION. The capitalization of the Company is
described in the Company's SEC Documents. The Company has not issued any capital
stock since September 30, 1999 other than (i) pursuant to employee benefit plans
disclosed in the Company's SEC Documents; (ii) a warrant to purchase 10,000
shares of the Company's Common Stock issued in connection with the Company's
acquisition of rights to certain intellectual property; and (iii) 3,700,000
shares of Common Stock issued in a private placement on October 6, 1999. The
Shares to be sold pursuant to the Agreements have been duly authorized, and when
issued and paid for in accordance with the terms of the Agreements, will be duly
and validly issued, fully paid and nonassessable. The outstanding shares of
capital stock of the Company have been duly and validly issued and are fully
paid and nonassessable, have been issued in compliance with all federal and
state securities laws, and were not issued in violation of any preemptive rights
or similar rights to subscribe for or purchase securities. Except as set forth
in or contemplated by the Company's SEC Documents or as otherwise described in
this Agreement, there are no outstanding rights (including, without limitation,
preemptive rights), warrants or options to acquire, or instruments convertible
into or exchangeable for, any unissued shares of capital stock or other equity
interest in the Company, or any contract, commitment, agreement, understanding
or arrangement of any kind to which the Company is a party and relating to the
issuance or sale of any capital stock of the Company, any such convertible or
exchangeable securities or any such rights, warrants or options. Without
limiting the foregoing, no preemptive right, co-sale right, registration right,
right of first refusal or other similar right exists with respect to the
issuance and sale of the Shares. Except as disclosed in the Company's SEC
Documents or as otherwise described in this Agreement, there

                                       3.
<PAGE>   5

are no stockholders agreements, voting agreements or other similar agreements
with respect to the Common Stock to which the Company is a party.

               4.5 LEGAL PROCEEDINGS. There is no legal or governmental
proceeding pending or, to the Company's knowledge, overtly threatened to which
the Company is or would be a party or of which the business or property of the
Company is or would be subject that is not disclosed in the Company's SEC
Documents that is required to be so disclosed.

               4.6 NO VIOLATIONS. The Company is not in violation of its
charter, bylaws or other organizational document, or in violation of any law,
administrative regulation, ordinance or order of any court or governmental
agency, arbitration panel or authority applicable to the Company, which
violation, individually or in the aggregate, would be reasonably likely to have
a Material Adverse Effect, or is in default (and there exists no condition
which, with the passage of time or otherwise, would constitute a default) in the
performance of any material bond, debenture, note or any other evidence of
indebtedness in any indenture, mortgage, deed of trust or any other material
agreement or instrument to which the Company is a party or by which the Company
is bound or by which the property of the Company is bound, which would,
individually or in the aggregate, be reasonably likely to have a Material
Adverse Effect.

               4.7 GOVERNMENTAL PERMITS, ETC. With the exception of the matters
which are dealt with separately in Sections 4.1, 4.12, and 4.13, the Company has
all necessary franchises, licenses, certificates and other authorizations from
any foreign, federal, state or local government or governmental agency,
department or body that are currently necessary for the operation of the
business of the Company as currently conducted except where the failure to
currently possess could not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect.

               4.8 INTELLECTUAL PROPERTY.

                      (a) The Company has ownership or license or legal right to
use all material patent, copyright, trade secret and trademark rights known by
it to be necessary to the conduct of the business of the Company as now
conducted (collectively, "Intellectual Property") other than Intellectual
Property generally available on commercial terms from other sources.

                      (b) All material licenses or other material agreements
under which (i) the Company is granted rights in Intellectual Property, other
than Intellectual Property generally available on commercial terms from other
sources, and (ii) the Company has granted rights to others in Intellectual
Property owned or licensed by the Company, are in full force and effect and, to
the knowledge of the Company, there is no material default by the Company or any
other party thereto.

                      (c) The Company believes it has taken all steps required
in accordance with sound business practice and business judgment to establish
and preserve its ownership of all material copyright, trade secret and other
proprietary rights with respect to its products and technology.

                                       4.
<PAGE>   6

                      (d) To the knowledge of the Company, the present business,
activities and products of the Company do not infringe any intellectual property
of any other person, except where such infringement would not, individually or
in the aggregate, have a Material Adverse Effect on the Company. Except as
described in the Company's SEC Documents, no proceeding charging the Company
with infringement of any adversely held Intellectual Property has been filed. To
the knowledge of the Company, the Company is not making unauthorized use of any
confidential information or trade secrets of any person. To the Company's
knowledge, the activities of the Company or any of its employees on behalf of
the Company do not violate any agreements or arrangements known to the Company
which any such employees have with other persons, if any.

               4.9 FINANCIAL STATEMENTS. The financial statements of the Company
and the related notes contained in the Company's SEC Documents present fairly,
in accordance with generally accepted accounting principles, the financial
position of the Company as of the dates indicated, and the results of its
operations and cash flows for the periods therein specified. Such financial
statements (including the related notes) have been prepared in accordance with
generally accepted accounting principles applied on a consistent basis
throughout the periods therein specified, except as disclosed in the Company's
SEC Documents.

               4.10 NO MATERIAL ADVERSE CHANGE. Except as disclosed in the
Company's press releases or other proprietary information provided to the
Investor in contemplation of this Offering, since September 30, 1999, there has
not been (i) any obligation, direct or contingent, that is material to the
Company, incurred by the Company, except obligations incurred in the ordinary
course of business, (ii) any dividend or distribution of any kind declared, paid
or made on the capital stock of the Company, (iii) any loss or damage (whether
or not insured) to the physical property of the Company which has been sustained
which, individually or in the aggregate, has a Material Adverse Effect; or (iv)
any other event or change that, individually or in the aggregate, would have a
Material Adverse Effect.

               4.11 NASDAQ COMPLIANCE. The Company's Common Stock is registered
pursuant to Section 12(g) of the Exchange Act and, as of the date hereof, is
listed on The Nasdaq National Market (the "Nasdaq Stock Market"), and the
Company has taken no action designed to, or likely to have the effect of,
terminating the registration of the Common Stock under the Exchange Act or
delisting the Common Stock from the Nasdaq Stock Market.

               4.12 REPORTING STATUS. The Company has filed in a timely manner
all documents that the Company was required to file under the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), during the 12 months
preceding the date of this Agreement. The following documents complied in all
material respects with the SEC's requirements as of their respective filing
dates, and the information contained therein as of the date thereof did not
contain an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein in
light of the circumstances under where they were made not misleading:

                      (a) The Company's Annual Report on Form 10-K for the year
ended December 31, 1998 (the "10-K");

                                       5.
<PAGE>   7

                      (b) The Company's Quarterly Reports on Form 10-Q for each
of the quarters ended March 31, 1999, June 30, 1999 and September 30, 1999; and

                      (c) All other documents, if any, filed by the Company with
the Securities and Exchange Commission since December 31, 1998 pursuant to the
reporting requirements of the Exchange Act.

               4.13 LISTING. The Company shall comply with all requirements of
the National Association of Securities Dealers, Inc. with respect to the
issuance of the Shares and the listing thereof on the Nasdaq Stock Market.

               4.14 FOREIGN CORRUPT PRACTICES. Neither the Company nor, to the
knowledge of the Company, any agent or other person acting on behalf of the
Company, have (i) directly or indirectly, used any corporate funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to
foreign or domestic political activity, (ii) made any unlawful payment to
foreign or domestic government officials or employees or to foreign or domestic
political parties or campaigns from corporate funds, (iii) failed to disclose
fully any contribution made by the Company or made by any person acting on its
behalf and of which the Company is aware in violation of law or (iv) violated in
any material respect any provision of the Foreign Corrupt Practices Act of 1977,
as amended.

               4.15 NO MANIPULATION OF STOCK. The Company has not taken and will
not, in violation of applicable law, take, any action designed to or that might
reasonably be expected to cause or result in unlawful manipulation of the price
of the Common Stock to facilitate the sale or resale of the Shares.

               4.16 NO MATERIAL SUBSIDIARIES. The Company has no subsidiaries
that, individually or in the aggregate, conduct any material business activities
or have any material assets or liabilities (whether fixed or contingent).

               4.17 LEGAL OPINION. The Company shall cause to be delivered to
the Investors by counsel to the Company a legal opinion pertaining to the
availability of an exemption from the registration provisions of the Securities
Act.

               4.18 OTHER AGREEMENTS. In the event that more than one Investor
participates in the Offering, each Stock Purchase Agreement between the Company
and each Investor shall contain substantially identical terms. In the event that
any Stock Purchase Agreement between the Company and another Investor in this
Offering shall contain terms more favorable to such Investor than provided
herein, after taking into account any other consideration provided, this
Agreement shall be amended to reflect those more favorable terms.

        5. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE INVESTOR.

               5.1 The Investor represents and warrants to, and covenants with,
the Company that: (i) the Investor is an "accredited investor" as defined in
Regulation D under the Securities Act and the Investor is also knowledgeable,
sophisticated and experienced in making, and is qualified to make decisions with
respect to, investments in shares presenting an investment

                                       6.
<PAGE>   8

decision like that involved in the purchase of the Shares, including investments
in securities issued by the Company and investments in comparable companies, and
has requested, received, reviewed and considered all information it deemed
relevant in making an informed decision to purchase the Shares; (ii) the
Investor is acquiring the number of Shares set forth on the Signature Page
hereto in the ordinary course of its business and for its own account for
investment only and with no present intention of distributing any of such Shares
or any arrangement or understanding with any other persons regarding the
distribution of such Shares; (iii) the Investor will not, directly or
indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit
any offers to buy, purchase or otherwise acquire or take a pledge of) any of the
Shares except in compliance with the Securities Act, applicable state securities
laws and the respective rules and regulations promulgated thereunder; (iv) the
Investor has answered all questions on the Signature Page hereto and the
Investor Questionnaire attached hereto as Exhibit B for use in preparation of
the Registration Statement and the answers thereto are true and correct in all
material respects as of the date hereof and will be true and correct in all
material respects as of the Closing Date; (v) the Investor will notify the
Company immediately of any material change in any of such information referred
to in the preceding clause (iv) until such time as the Investor has sold all of
its Shares or until the Company is no longer required to keep the Registration
Statement effective; and (vi) the Investor has, in connection with its decision
to purchase the number of Shares set forth on the signature page hereto, relied
only upon the Company Information provided to the Investor by the Company in
contemplation of this offering and the representations and warranties of the
Company contained herein. Investor understands that its acquisition of the
Shares has not been registered under the Securities Act of 1933, as amended (the
"Securities Act"), or registered or qualified under any state securities law in
reliance on specific exemptions therefrom, which exemptions may depend upon,
among other things, the bona fide nature of the Investor's investment intent as
expressed herein. Investor has completed or caused to be completed and delivered
to the Company the Investor Questionnaire attached hereto Exhibit B, which
questionnaire is true and correct in all material respects.

               5.2 The Investor acknowledges, represents and agrees that no
action has been or will be taken in any jurisdiction outside the United States
by the Company or the Placement Agent that would permit an offering of the
Shares, or possession or distribution of offering materials in connection with
the issue of the Shares, in any jurisdiction outside the United States where
action for that purpose is required. Each Investor outside the United States
will comply with all applicable laws and regulations in each foreign
jurisdiction in which it purchases, offers, sells or delivers Shares or has in
its possession or distributes any offering material, in all cases at its own
expense. The Placement Agents have not been authorized to make any
representation or use any information in connection with the issue, placement,
purchase and sale of the Shares.

               5.3 The Investor hereby covenants with the Company not to make
any sale of the Shares without complying in all material respects with the
provisions of this Agreement, including Section 7.2 hereof, and, if applicable,
without effectively causing the prospectus delivery requirement under the
Securities Act to be satisfied, and the Investor acknowledges that the
certificates evidencing the Shares will be imprinted with a legend that
prohibits their transfer except in accordance therewith. The Investor
acknowledges that there may occasionally be times when the Company, based on the
advice of its counsel, determines that it must suspend the use of the Prospectus
forming a part of the Registration Statement (as defined herein) until such time
as

                                       7.
<PAGE>   9

an amendment to the Registration Statement has been filed by the Company and
declared effective by the SEC or until the Company has amended or supplemented
such Prospectus.

               5.4 The Investor further represents and warrants to, and
covenants with, the Company that (i) the Investor has full right, power,
authority and capacity to enter into this Agreement and to consummate the
transactions contemplated hereby and has taken all necessary action to authorize
the execution, delivery and performance of this Agreement, and (ii) this
Agreement constitutes a valid and binding obligation of the Investor enforceable
against the Investor in accordance with its terms, except as enforceability may
be limited by applicable bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting creditors' and contracting parties' rights generally and
except as enforceability may be subject to general principles of equity
(regardless of whether such enforceability is considered in a proceeding in
equity or at law) and except as the indemnification agreements of the Investors
herein may be legally unenforceable.

               5.5 Other than in a transaction exempt from registration under
the Securities Act, Investor will not, prior to the effectiveness of the
Registration Statement, sell, offer to sell, solicit offers to buy, dispose of,
loan, pledge or grant any right with respect to (collectively, a "Disposition"),
the Common Stock of the Company, nor will Investor engage in any hedging or
other transaction which is designed to or could reasonably be expected to lead
to or result in a Disposition of Common Stock of the Company by the Investor or
any other person or entity. Such prohibited hedging or other transactions would
include, without limitation, effecting any short sale or having in effect any
short position (whether or not such sale or position is against the box and
regardless of when such position was entered into) or any purchase, sale or
grant of any right (including, without limitation, any put or call option) with
respect to the Common Stock of the Company or with respect to any security
(other than a broad-based market basket or index) that includes, relates to or
derives any significant part of its value from the Common Stock of the Company.

               5.6 The Investor understands that nothing in this Agreement or
any other materials presented to the Investor in connection with the purchase
and sale of the Shares constitutes legal, tax or investment advice. The Investor
has consulted such legal, tax and investment advisors as it, in its sole
discretion, has deemed necessary or appropriate in connection with its purchase
of Shares.

        6. SURVIVAL OF REPRESENTATIONS, WARRANTIES AND AGREEMENTS.
Notwithstanding any investigation made by any party to this Agreement or by the
Placement Agents, all covenants, agreements, representations and warranties made
by the Company and the Investor herein shall survive the execution of this
Agreement, the delivery to the Investor of the Shares being purchased and the
payment therefor.

        7. REGISTRATION OF THE SHARES; COMPLIANCE WITH THE SECURITIES ACT.

               7.1 REGISTRATION PROCEDURES AND EXPENSES. The Company shall:

                      (a) subject to receipt of necessary information from the
Investors, prepare and file with the SEC, as soon as practicable, but in no
event later than thirty (30) days

                                       8.
<PAGE>   10

after the Closing Date, a registration statement on Form S-3 (the "Registration
Statement") to enable the resale of the Shares by the Investors from time to
time through the automated quotation system of the Nasdaq Stock Market or in
privately-negotiated transactions; provided, however, that in the even Form S-3
is not available to the Company at any time after the date of this Agreement,
the Company shall file such other form as may be available if holders who hold
Shares with a market value of at least One Million Dollars ($1,000,000) deliver
a written request to the Company that the Company do so, where such market value
is determined as of the date of such written request. Any such registration
statement filed pursuant to the above provision shall be considered a
"Registration Statement" for purposes of Agreement.

                      (b) use its reasonable efforts, subject to receipt of
necessary information from the Investors, to cause the Registration Statement to
become effective as soon as practicable, and shall use its best efforts, subject
to receipt of necessary information from the Investors, to cause the
Registration Statement to become effective not later than one hundred twenty
(120) days after the Closing Date. In the event such Registration Statement is
not effective at the expiration of such 120-day period, the Company shall
continue to use all reasonable commercial efforts to cause it to become
effective until it becomes effective.

                      (c) prepare and file with the SEC such amendments and
supplements to the Registration Statement and the Prospectus used in connection
therewith as may be necessary to keep the Registration Statement current and
effective for a period not exceeding, with respect to each Investor's Shares
purchased hereunder, the earlier of (i) the second anniversary of the Closing
Date, (ii) the date on which the Investor may sell all Shares then held by the
Investor without restriction under Rule 144(k) of the Securities Act or (iii)
such time as all Shares purchased by such Investor in this Offering have been
sold pursuant to a registration statement.

                      (d) furnish to the Placement Agents and to the Investor
with respect to the Shares registered under the Registration Statement such
number of copies of the Registration Statement, Prospectuses and Preliminary
Prospectuses in conformity with the requirements of the Securities Act and such
other documents as they may reasonably request, in order to facilitate the
public sale or other disposition of all or any of the Shares by the Investor,
provided, however, that the obligation of the Company to deliver copies of
Prospectuses or Preliminary Prospectuses to the Investor shall be subject to the
receipt by the Company of reasonable assurances from the Investor that the
Investor will comply with the applicable provisions of the Securities Act and of
such other securities or blue sky laws as may be applicable in connection with
any use of such Prospectuses or Preliminary Prospectuses;

                      (e) file documents required of the Company for normal blue
sky clearance in states specified in writing by the Investor, provided, however,
that the Company shall not be required to qualify to do business or consent to
service of process generally in any jurisdiction in which it is not now so
qualified or has not so consented;

                      (f) bear all expenses in connection with the procedures in
paragraph (a) through (e) of this Section 7.1 and the registration of the Shares
pursuant to the Registration Statement; and

                                       9.
<PAGE>   11

                      (g) advise the Investors, promptly after it shall receive
notice or obtain knowledge of the issuance of any stop order by the SEC delaying
or suspending the effectiveness of the Registration Statement or of the
initiation of any proceeding for that purpose; and it will promptly use its
commercially reasonable efforts to prevent the issuance of any stop order or to
obtain its withdrawal at the earliest possible moment if such stop order should
be issued.

        It shall be a condition precedent to the obligations of the Company to
take any action pursuant to this Section 7.1 that the Investor shall furnish to
the Company such information regarding itself, the Shares to be sold by
Investor, and the intended method of disposition of such securities as shall be
reasonably required to effect the registration of the Shares.

        The Company understands that the Investor disclaims being an
underwriter, but the Investor being deemed an underwriter by the SEC shall not
relieve the Company of any obligations it has hereunder, provided, however, that
if the Company receives notification from the SEC that the Investor is deemed an
underwriter, then the period by which the Company is obligated to submit an
acceleration request to the SEC shall be extended to the earlier of (i) the 90th
day after such SEC notification, or (ii) 120 days after the initial filing of
the Registration Statement with the SEC.

               7.2 TRANSFER OF SHARES AFTER REGISTRATION; SUSPENSION.

                      (a) The Investor agrees that it will not effect any
Disposition of the Shares or its right to purchase the Shares that would
constitute a sale within the meaning of the Securities Act except (i) as
contemplated in the Registration Statement referred to in Section 7.1 and as
described below, or (ii) in a transaction exempt from registration under the
Securities Act, and that it will promptly notify the Company of any changes in
the information set forth in the Registration Statement regarding the Investor
or its plan of distribution.

                      (b) Subject to paragraph (c) below (if applicable), the
Company shall: (i) if deemed necessary by the Company, prepare and file from
time to time with the SEC a post-effective amendment to the Registration
Statement or a supplement to the related Prospectus or a supplement or amendment
to any document incorporated therein by reference or file any other required
document so that such Registration Statement will not contain an untrue
statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein not misleading, and
so that, as thereafter delivered to purchasers of the Shares being sold
thereunder, such Prospectus will not contain an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they
were made, not misleading; (ii) provide the Investor copies of any documents
filed pursuant to Section 7.2(b)(i); and (iii) inform each Investor that the
Company has complied with its obligations in Section 7.2(b)(i) (or that, if the
Company has filed a post-effective amendment to the Registration Statement which
has not yet been declared effective, the Company will notify the Investor to
that effect, will use its reasonable efforts to secure the effectiveness of such
post-effective amendment as promptly as possible and will promptly notify the
Investor pursuant to Section 7.2(b)(i) hereof when the amendment has become
effective).

                                      10.
<PAGE>   12

                      (c) Subject to paragraph (d) below, in the event: (i) of
any request by the SEC or any other federal or state governmental authority
during the period of effectiveness of the Registration Statement for amendments
or supplements to a Registration Statement or related Prospectus or for
additional information; (ii) of the issuance by the SEC or any other federal or
state governmental authority of any stop order suspending the effectiveness of a
Registration Statement or the initiation of any proceedings for that purpose;
(iii) of the receipt by the Company of any notification with respect to the
suspension of the qualification or exemption from qualification of any of the
Shares for sale in any jurisdiction or the initiation of any proceeding for such
purpose; or (iv) of any event or circumstance which necessitates the making of
any changes in the Registration Statement or Prospectus, or any document
incorporated or deemed to be incorporated therein by reference, so that, in the
case of the Registration Statement, it will not contain any untrue statement of
a material fact or any omission to state a material fact required to be stated
therein or necessary to make the statements therein not misleading, and that in
the case of the Prospectus, it will not contain any untrue statement of a
material fact or any omission to state a material fact required to be stated
therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading; then the Company shall
deliver a certificate in writing to the Investor (the "Suspension Notice") to
the effect of the foregoing and, upon receipt of such Suspension Notice, the
Investor will refrain from selling any Shares pursuant to the Registration
Statement (a "Suspension") until the Investor's receipt of copies of a
supplemented or amended Prospectus prepared and filed by the Company, or until
it is advised in writing by the Company that the current Prospectus may be used,
and has received copies of any additional or supplemental filings that are
incorporated or deemed incorporated by reference in any such Prospectus. In the
event of any Suspension, the Company will use its reasonable efforts to cause
the use of the Prospectus so suspended to be resumed as soon as reasonably
practicable within 20 business days after delivery of a Suspension Notice to the
Investors. In addition to and without limiting any other remedies (including,
without limitation, at law or at equity) available to the Investor, the Investor
shall be entitled to specific performance in the event that the Company fails to
comply with the provisions of this Section 7.2(c).

                      (d) Notwithstanding the foregoing paragraphs of this
Section 7.2, the Investor shall not be prohibited from selling Shares under the
Registration Statement as a result of Suspensions on more than two occasions of
not more than 30 days each in any twelve month period, unless, in the good faith
judgment of the Company's Board of Directors, upon advice of counsel, the sale
of Shares under the Registration Statement in reliance on this paragraph 7.2(d)
would be reasonably likely to cause a violation of the Securities Act or the
Exchange Act and result in potential liability to the Company.

                      (e) Provided that a Suspension is not then in effect the
Investor may sell Shares under the Registration Statement, provided that it
arranges for delivery of a current Prospectus to the transferee of such Shares.
Upon receipt of a request therefor, the Company has agreed to provide an
adequate number of current Prospectuses to the Investor and to supply copies to
any other parties requiring such Prospectuses.

                      (f) In the event of a sale of Shares by the Investor, the
Investor must also deliver to the Company's transfer agent, with a copy to the
Company, a Certificate of

                                      11.
<PAGE>   13

Subsequent Sale substantially in the form attached hereto as Exhibit C, so that
the shares may be properly transferred.

               7.3 INDEMNIFICATION. For the purpose of this Section 7.3:

                      (a) the term "Selling Stockholder" shall include the
Investor and any affiliate, officer, director, employee or control person (as
defined by Section 15 of the Securities Act) of such Investor;

                      (b) the term "Registration Statement" shall include any
final Prospectus, exhibit, supplement or amendment included in or relating to
the Registration Statement referred to in Section 7.1; and

                      (c) the term "untrue statement" shall include any untrue
statement or alleged untrue statement, or any omission or alleged omission to
state in the Registration Statement a material fact required to be stated
therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading.

                             (i) The Company agrees to indemnify and hold
harmless each Selling Stockholder from and against any losses, claims, damages
or liabilities to which such Selling Stockholder may become subject (under the
Securities Act or otherwise) insofar as such losses, claims, damages or
liabilities (or actions or proceedings in respect thereof) arise out of, or are
based upon (i) any untrue statement of a material fact contained in the
Registration Statement, or (ii) any failure by the Company to fulfill any
undertaking included in the Registration Statement, and the Company will
reimburse such Selling Stockholder for any reasonable legal or other expenses
reasonably incurred in investigating, defending or preparing to defend any such
action, proceeding or claim, provided, however, that the Company shall not be
liable in any such case to the extent that such loss, claim, damage or liability
arises out of, or is based upon, an untrue statement made in such Registration
Statement in reliance upon and in conformity with written information furnished
to the Company by or on behalf of such Selling Stockholder specifically for use
in preparation of the Registration Statement or any statement or omission in any
Prospectus that is corrected in any subsequent Prospectus that was delivered to
the Investor prior to the pertinent sale or sales by the Investor.

                             (ii) The Investor agrees to indemnify and hold
harmless the Company (and each person, if any, who controls the Company within
the meaning of Section 15 of the Securities Act, each officer of the Company who
signs the Registration Statement and each director of the Company) from and
against any losses, claims, damages or liabilities to which the Company (or any
such officer, director or controlling person) may become subject (under the
Securities Act or otherwise), insofar as such losses, claims, damages or
liabilities (or actions or proceedings in respect thereof) arise out of, or are
based upon any untrue statement of a material fact contained in the Registration
Statement if such untrue statement was made in reliance upon and in conformity
with written information furnished by or on behalf of the Investor specifically
for use in preparation of the Registration Statement, and the Investor will
reimburse the Company (or such officer, director or controlling person), as the
case may be, for any legal or other expenses reasonably incurred in
investigating, defending or preparing to defend any such action, proceeding or
claim.

                                      12.
<PAGE>   14

                             (iii) Promptly after receipt by any indemnified
person of a notice of a claim or the beginning of any action in respect of which
indemnity is to be sought against an indemnifying person pursuant to this
Section 7.3, such indemnified person shall notify the indemnifying person in
writing of such claim or of the commencement of such action, but the omission to
so notify the indemnifying party will not relieve it from any liability which it
may have to any indemnified party under this Section 7.3 (except to the extent
that such omission materially and adversely affects the indemnifying party's
ability to defend such action) or from any liability otherwise than under this
Section 7.3. Subject to the provisions hereinafter stated, in case any such
action shall be brought against an indemnified person, the indemnifying person
shall be entitled to participate therein, and, to the extent that it shall elect
by written notice delivered to the indemnified party promptly after receiving
the aforesaid notice from such indemnified party, shall be entitled to assume
the defense thereof, with counsel reasonably satisfactory to such indemnified
person. After notice from the indemnifying person to such indemnified person of
its election to assume the defense thereof, such indemnifying person shall not
be liable to such indemnified person for any legal expenses subsequently
incurred by such indemnified person in connection with the defense thereof,
provided, however, that if there exists or shall exist a conflict of interest
that would make it inappropriate, in the reasonable opinion of counsel to the
indemnified person, for the same counsel to represent both the indemnified
person and such indemnifying person or any affiliate or associate thereof, the
indemnified person shall be entitled to retain its own counsel at the expense of
such indemnifying person; provided, however, that no indemnifying person shall
be responsible for the fees and expenses of more than one separate counsel
(together with appropriate local counsel) for all indemnified parties (unless in
the reasonable judgment of an indemnified party, there exists a conflict of
interest between such indemnified person and any other indemnified person, in
which case the indemnifying person shall be obligated to pay the reasonable fees
and expenses of additional counsel). In no event shall any indemnifying person
be liable in respect of any amounts paid in settlement of any action unless the
indemnifying person shall have approved the terms of such settlement; provided
that such consent shall not be unreasonably withheld. No indemnifying person
shall, without the prior written consent of the indemnified person, effect any
settlement of any pending or threatened proceeding in respect of which any
indemnified person is or could have been a party and indemnification could have
been sought hereunder by such indemnified person, unless such settlement
includes an unconditional release of such indemnified person from all liability
on claims that are the subject matter of such proceeding.

                             (iv) If the indemnification provided for in this
Section 7.3 is unavailable to or insufficient to hold harmless an indemnified
party under subsection (a) or (b) above in respect of any losses, claims,
damages or liabilities (or actions or proceedings in respect thereof) referred
to therein, then each indemnifying party shall contribute to the amount paid or
payable by such indemnified party as a result of such losses, claims, damages or
liabilities (or actions in respect thereof) in such proportion as is appropriate
to reflect the relative fault of the Company on the one hand and the Investors
on the other in connection with the statements or omissions or other matters
which resulted in such losses, claims, damages or liabilities (or actions in
respect thereof), as well as any other relevant equitable considerations. The
relative fault shall be determined by reference to, among other things, in the
case of an untrue statement, whether the untrue statement relates to information
supplied by the Company on the one hand or an Investor on the other and the
parties' relative intent, knowledge, access to information and

                                      13.
<PAGE>   15

opportunity to correct or prevent such untrue statement. The Company and the
Investors agree that it would not be just and equitable if contribution pursuant
to this subsection (d) were determined by pro rata allocation (even if the
Investors were treated as one entity for such purpose) or by any other method of
allocation which does not take into account the equitable considerations
referred to above in this subsection (d). The amount paid or payable by an
indemnified party as a result of the losses, claims, damages or liabilities (or
actions in respect thereof) referred to above in this subsection (d) shall be
deemed to include any legal or other expenses reasonably incurred by such
indemnified party in connection with investigating or defending any such action
or claim. Notwithstanding the provisions of this subsection (d), no Investor
shall be required to contribute any amount in excess of the amount by which the
gross amount received by the Investor from the sale of the Shares to which such
loss relates exceeds the amount of any damages which such Investor has otherwise
been required to pay by reason of such untrue statement. No person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. The Investors' obligations in this
subsection to contribute are several in proportion to their sales of Shares to
which such loss relates and not joint.

                             (v) The parties to this Agreement hereby
acknowledge that they are sophisticated business persons who were represented by
counsel during the negotiations regarding the provisions hereof including,
without limitation, the provisions of this Section 7.3, and are fully informed
regarding said provisions. They further acknowledge that the provisions of this
Section 7.3 fairly allocate the risks in light of the ability of the parties to
investigate the Company and its business in order to assure that adequate
disclosure is made in the Registration Statement as required by the Act and the
Exchange Act. The parties are advised that federal or state public policy as
interpreted by the courts in certain jurisdictions may be contrary to certain of
the provisions of this Section 7.3, and the parties hereto hereby expressly
waive and relinquish any right or ability to assert such public policy as a
defense to a claim under this Section 7.3 and further agree not to attempt to
assert any such defense.

               7.4 TERMINATION OF CONDITIONS AND OBLIGATIONS. The conditions
precedent imposed by Section 5 or this Section 7 upon the transferability of the
Shares shall cease and terminate as to any particular number of the Shares when
such Shares shall have been effectively registered under the Securities Act and
sold or otherwise disposed of in accordance with the intended method of
disposition set forth in the Registration Statement covering such Shares or at
such time as an opinion of counsel satisfactory to the Company shall have been
rendered to the effect that such conditions are not necessary in order to comply
with the Securities Act.

               7.5 INFORMATION AVAILABLE. So long as the Registration Statement
is effective covering the resale of Shares owned by the Investor, the Company
will furnish to the Investor:

                      (a) as soon as practicable after it is available, one copy
of (i) its Annual Report to Stockholders (which Annual Report shall contain
financial statements audited in accordance with generally accepted accounting
principles by a national firm of certified public accountants) and (ii) if not
included in substance in the Annual Report to Stockholders, its Annual Report on
Form 10-K (the foregoing, in each case, excluding exhibits);

                                      14.
<PAGE>   16

                      (b) upon the reasonable request of the Investor, all
exhibits excluded by the parenthetical to subparagraph (a)(ii) of this Section
7.5 as filed with the SEC and all other information that is made available to
shareholders; and

                      (c) upon the reasonable request of the Investor, an
adequate number of copies of the Prospectuses to supply to any other party
requiring such Prospectuses; and the Company, upon the reasonable request of the
Investor, will meet with the Investor or a representative thereof at the
Company's headquarters to discuss all information relevant for disclosure in the
Registration Statement covering the Shares and will otherwise cooperate with any
Investor conducting an investigation for the purpose of reducing or eliminating
such Investor's exposure to liability under the Securities Act, including the
reasonable production of information at the Company's headquarters; provided,
that the Company shall not be required to disclose any confidential information
to or meet at its headquarters with any Investor until and unless the Investor
shall have entered into a confidentiality agreement in form and substance
reasonably satisfactory to the Company with the Company with respect thereto.

        8. NOTICES. All notices, requests, consents and other communications
hereunder shall be in writing, shall be mailed (A) if within domestic United
States by first-class registered or certified airmail, or nationally recognized
overnight express courier, postage prepaid, or by facsimile, or (B) if delivered
from outside the United States, by International Federal Express or facsimile,
and shall be deemed given (i) if delivered by first-class registered or
certified mail domestic, three business days after so mailed, (ii) if delivered
by nationally recognized overnight carrier, one (1) business day after so
mailed, (iii) if delivered by International Federal Express, two (2) business
days after so mailed, (iv) if delivered by facsimile, upon electric confirmation
of receipt and shall be delivered as addressed as follows:

                      (a)    if to the Company, to:

                             Amylin Pharmaceuticals, Inc.
                             9373 Towne Centre Drive
                             San Diego, California 92121

                             Attn: Nancy K. Dahl
                             Vice President and General Counsel
                             Phone:  (858) 642-7271
                             Telecopy:  (858) 552-1939

                      (b)    with a copy mailed to:

                             Cooley Godward LLP
                             4365 Executive Drive, Suite 1100
                             San Diego, CA  92121

                             Attn: Thomas A. Coll
                             Phone: (858) 550-6013
                             Telecopy: (858) 453-3555

                                      15.
<PAGE>   17

                      (c) if to the Investor, at its address on the Signature
Page hereto, or at such other address or addresses as may have been furnished to
the Company in writing.

        9. CHANGES. This Agreement may not be modified or amended except
pursuant to an instrument in writing signed by the Company and the Investor.

        10. HEADINGS. The headings of the various sections of this Agreement
have been inserted for convenience of reference only and shall not be deemed to
be part of this Agreement.

        11. SEVERABILITY. In case any provision contained in this Agreement
should be invalid, illegal or unenforceable in any respect, the validity,
legality and enforceability of the remaining provisions contained herein shall
not in any way be affected or impaired thereby.

        12. GOVERNING LAW. This Agreement shall be governed by, and construed in
accordance with, the internal laws of the State of California, without giving
effect to the principles of conflicts of law.

        13. COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall constitute an original, but all of which, when
taken together, shall constitute but one instrument, and shall become effective
when one or more counterparts have been signed by each party hereto and
delivered to the other parties.

        14. CONFIDENTIAL DISCLOSURE AGREEMENT. Notwithstanding any provision of
this Agreement to the contrary, any confidential disclosure agreement previously
executed by the Company and the Investor in connection with the transactions
contemplated by this Agreement shall remain in full force and effect in
accordance with its terms following the execution of this Agreement and the
consummation of the transactions contemplated hereby.

                                      16.
<PAGE>   18

                                    EXHIBIT A

                          AMYLIN PHARMACEUTICALS, INC.

                         STOCK CERTIFICATE QUESTIONNAIRE

        Pursuant to Section 5 of the Agreement, please provide us with the
following information:

1.      The exact name that your Shares are to be        _______________________
        registered in (this is the name that will appear
        on your stock certificate(s)). You may use a
        nominee name if appropriate:

2.      The relationship between the Investor and the    _______________________
        registered holder listed in response to item 1
        above:

3.      The mailing address of the registered holder     _______________________
        listed in response to item 1 above:

4.      The Social Security Number or Tax                _______________________
        Identification Number of the registered holder
        listed in the response to item 1 above:

A-1.
<PAGE>   19
                                    EXHIBIT B

                          AMYLIN PHARMACEUTICALS, INC.

                             INVESTOR QUESTIONNAIRE

                (ALL INFORMATION WILL BE TREATED CONFIDENTIALLY)

To:  Amylin Pharmaceuticals, Inc.

        This Investor Questionnaire ("Questionnaire") must be completed by each
potential investor in connection with the offer and sale of the shares of the
common stock, par value $0.001 per share, of Amylin Pharmaceuticals, Inc. (the
"Securities"). The Securities are being offered and sold by Amylin
Pharmaceuticals, Inc. (the "Corporation") without registration under the
Securities Act of 1933, as amended (the "Act"), and the securities laws of
certain states, in reliance on the exemptions contained in Section 4(2) of the
Act and on Regulation D promulgated thereunder and in reliance on similar
exemptions under applicable state laws. The Corporation must determine that a
potential investor meets certain suitability requirements before offering or
selling Securities to such investor. The purpose of this Questionnaire is to
assure the Corporation that each investor will meet the applicable suitability
requirements. The information supplied by you will be used in determining
whether you meet such criteria, and reliance upon the private offering exemption
from registration is based in part on the information herein supplied.

        This Questionnaire does not constitute an offer to sell or a
solicitation of an offer to buy any security. Your answers will be kept strictly
confidential. However, by signing this Questionnaire you will be authorizing the
Corporation to provide a completed copy of this Questionnaire to such parties as
the Corporation deems appropriate in order to ensure that the offer and sale of
the Securities will not result in a violation of the Act or the securities laws
of any state and that you otherwise satisfy the suitability standards applicable
to purchasers of the Securities. All potential investors must answer all
applicable questions and complete, date and sign this Questionnaire. Please
print or type your responses and attach additional sheets of paper if necessary
to complete your answers to any item.

A.      BACKGROUND INFORMATION

Name:
     ---------------------------------------------------------------------------

Business Address:
                 ---------------------------------------------------------------
                               (Number and Street)

--------------------------------------------------------------------------------
(City)                              (State)                       (Zip Code)

Telephone Number:  (     )
                          ------------------------------------------------------

Residence Address:
                  --------------------------------------------------------------
                               (Number and Street)

--------------------------------------------------------------------------------
(City)                              (State)                       (Zip Code)

Telephone Number:  (     )
                          ------------------------------------------------------

If an individual:

Age:              Citizenship:               Where registered to vote:
    ------                    ----------                              ----------

If a corporation, partnership, limited liability company, trust or other entity:

Type of entity:
               -----------------------------------------------------------------

State of formation:                           Date of formation:
                   --------------                               ----------------

Social Security or Taxpayer Identification No.
                                              ----------------------------------

Send all correspondence to (check one):       Residence Address
                                         ----
                                              Business Address
                                         ----

B-1.
<PAGE>   20

B.      STATUS AS ACCREDITED INVESTOR

The undersigned is an "accredited investor" as such term is defined in
Regulation D under the Act, as at the time of the sale of the Securities the
undersigned falls within one or more of the following categories (Please initial
one or more, as applicable):(1)

_____(1) a bank as defined in Section 3(a)(2) of the Act, or a savings and loan
association or other institution as defined in Section 3(a)(5)(A) of the Act
whether acting in its individual or fiduciary capacity; a broker or dealer
registered pursuant to Section 15 of the Securities Exchange Act of 1934; an
insurance company as defined in Section 2(13) of the Act; an investment company
registered under the Investment Corporation Act of 1940 or a business
development company as defined in Section 2(a)(48) of that Act; a Small Business
Investment Corporation licensed by the U.S. Small Business Administration under
Section 301(c) or (d) of the Small Business Investment Act of 1958; a plan
established and maintained by a state, its political subdivisions, or any agency
or instrumentality of a state or its political subdivisions for the benefit of
its employees, if such plan has total assets in excess of $5,000,000; an
employee benefit plan within the meaning of the Employee Retirement Income
Security Act of 1974 if the investment decision is made by a plan fiduciary, as
defined in Section 3(21) of such Act, which is either a bank, savings and loan
association, insurance company, or registered investment adviser, or if the
employee benefit plan has total assets in excess of $5,000,000 or, if a
self-directed plan, with the investment decisions made solely by persons that
are accredited investors;(1)

_____(2) a private business development company as defined in Section 202(a)(22)
of the Investment Adviser Act of 1940;

_____(3) an organization described in Section 501(c)(3) of the Internal Revenue
Code of 1986, as amended, corporation, Massachusetts or similar business trust,
or partnership, not formed for the specific purpose of acquiring the Securities
offered, with total assets in excess of $5,000,000;

_____(4) a natural person whose individual net worth, or joint net worth with
that person's spouse, at the time of such person's purchase of the Securities
exceeds $1,000,000;

_____(5) a natural person who had an individual income in excess of $200,000 in
each of the two most recent years or joint income with that person's spouse in
excess of $300,000 in each of those years and has a reasonable expectation of
reaching the same income level in the current year;

_____(6) a trust, with total assets in excess of $5,000,000, not formed for the
specific purpose of acquiring the Securities offered, whose purchase is directed
by a sophisticated person as described in Rule 506(b)(2)(ii) of Regulation D;
and

_____(7) an entity in which all of the equity owners are accredited investors
(as defined above).

----------

(1) As used in this Questionnaire, the term "net worth" means the excess of
total assets over total liabilities. In computing net worth for the purpose of
subsection (4), the principal residence of the investor must be valued at cost,
including cost of improvements, or at recently appraised value by an
institutional lender making a secured loan, net of encumbrances. In determining
income, the investor should add to the investor's adjusted gross income any
amounts attributable to tax exempt income received, losses claimed as a limited
partner in any limited partnership, deductions claimed for depiction,
contributions to an IRA or KEOGH retirement plan, alimony payments, and any
amount by which income from long-term capital gains has been reduced in arriving
at adjusted gross income.

B-2.
<PAGE>   21

C.      REPRESENTATIONS

The undersigned hereby represents and warrants to the Corporation as follows:

        1. Any purchase of the Securities would be solely for the account of the
undersigned and not for the account of any other person or with a view to any
resale, fractionalization, division, or distribution thereof.

        2. The information contained herein is complete and accurate and may be
relied upon by the Corporation, and the undersigned will notify the Corporation
immediately of any material change in any of such information occurring prior to
the closing, if any, with respect to the purchase of Securities by the
undersigned or any co-purchaser.

        3. There are no suits, pending litigation, or claims against the
undersigned that could materially affect the net worth of the undersigned as
reported in this Questionnaire.

        4. The undersigned acknowledges that there may occasionally be times
when the Corporation, based on the advice of its counsel, determines that it
must suspend the use of the Prospectus forming a part of the Registration
Statement (as such terms are defined in the Stock Purchase Agreement to which
this Questionnaire is attached) until such time as an amendment to the
Registration Statement has been filed by the Company and declared effective by
the Securities and Exchange Commission or until the Corporation has amended or
supplemented such Prospectus. The undersigned is aware that, in such event, the
Securities will not be subject to ready liquidation, and that any Securities
purchased by the undersigned would have to be held during such suspension. The
overall commitment of the undersigned to investments which are not readily
marketable is not excessive in view of the undersigned's net worth and financial
circumstances, and any purchase of the Securities will not cause such commitment
to become excessive. The undersigned is able to bear the economic risk of an
investment in the Securities.

        5. In addition to reviewing the Corporation's Confidential Offering
Memorandum, the undersigned has carefully considered the potential risks
relating to the Corporation and a purchase of the Securities, and fully
understands that the Securities are speculative investments which involve a high
degree of risk of loss of the undersigned's entire investment. Among others, the
undersigned has carefully considered each of the risks described under the
heading "Risk Factors" in the Corporation's most recent annual report on Form
10-K.

IN WITNESS WHEREOF, the undersigned has executed this Questionnaire this _____
day of _____________, 2000, and declares under oath that it is truthful and
correct.

                                   Print Name

                                   By:
                                      ------------------------------------------
                                   Signature

                                   Title:
                                         ---------------------------------------
                                         (required for any purchaser that is
                                         a corporation, partnership, trust or
                                         other entity)

B-3.
<PAGE>   22

                                    EXHIBIT C

                          AMYLIN PHARMACEUTICALS, INC.

                         CERTIFICATE OF SUBSEQUENT SALE

ChaseMellon Shareholder Services

        RE:    Sale of Shares of Common Stock of Amylin Pharmaceuticals, Inc.
               (the "Company") pursuant to the Company's Prospectus dated
               _______________, 2000 (the "Prospectus")

Dear Sir/Madam:

        The undersigned hereby certifies, in connection with the sale of shares
of Common Stock of the Company included in the table of Selling Shareholders in
the Prospectus, that the undersigned has sold the Shares pursuant to the
Prospectus and in a manner described under the caption "Plan of Distribution" in
the Prospectus and that such sale complies with all applicable securities laws,
including, without limitation, the Prospectus delivery requirements of the
Securities Act of 1933, as amended.

        Selling Shareholder (the beneficial owner):
                                                   -----------------------------

        Record Holder (e.g., if held in name of nominee):
                                                         -----------------------

        Restricted Stock Certificate No.(s):
                                            ------------------------------------

        Number of Shares Sold:
                              --------------------------------------------------

        Date of Sale:
                     -----------------------------------------------------------

        In the event that you receive a stock certificate(s) representing more
shares of Common Stock than have been sold by the undersigned, then you should
return to the undersigned a newly issued certificate for such excess shares in
the name of the Record Holder and BEARING A RESTRICTIVE LEGEND. Further, you
should place a stop transfer on your records with regard to such certificate.

                                        Very truly yours,

                                        By:
                                           -------------------------------------

                                        Print Name:
                                                   -----------------------------

                                        Title:
                                              ----------------------------------

Dated:
      -------------------

cc:     Legal Department
        Amylin Pharmaceuticals, Inc.
        9373 Towne Centre Drive
        San Diego, California  92121

<PAGE>   23

                             SCHEDULE OF PURCHASERS

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------
                                                       COMMON STOCK TO BE ISSUED
                 STOCKHOLDER                                 FOR INVESTMENT
--------------------------------------------------------------------------------
<S>                                                    <C>
Allen Andersson                                                1,333,334

Ralph M. D'Annucci                                                50,000

Clipperbay & Co., as Custodian for SMALLCAP                    1,845,833
World Fund, Inc.

Rescueboat & Co., as Custodian for The                         3,000,000
Growth Fund of America, Inc.

Pirate Ship & Co., as Custodian for Invesco                      325,000
Global Health Sciences Fund

SeaLion & Co., as Custodian for Invesco                          295,000
Health Sciences Fund

Above Anchor & Co., as Custodian for Invesco                       8,000
VIF - Health Sciences Fund

"Roytor & Co.", in Trust for State Street                         40,000
Trust Co. Canada Fund #ZM 75, as Custodian
for AIM Funds Management Inc., on behalf of
AIM Global Health Sciences Class of AIM
Global Fund Inc.

"Roytor & Co.", in Trust for State Street                         82,000
Trust Co. Canada Fund #KG 56, as Custodian
for AIM Funds Management Inc., on behalf of
AIM Global Health Sciences Fund

Deerfield Partners L.P.                                          740,000

Deerfield International Limited                                  260,000

Rumsfeld Family Trust                                             10,417

Donald H. Rumsfeld                                                10,417

MCP Global Corp. Ltd.                                            100,000

United Capital Management Inc.                                   100,000

Deltec Asset Management  Corporation                              50,000

Narragansett I, LP                                                60,833

Narragansett Offshore, Ltd.                                       22,500

TOTAL                                                          8,333,334
</TABLE>SUBCLASS A-2 FLOATING RATE ASSET-BACKED NOTE, SERIES 1999-1

<PAGE>

                             AIRCRAFT FINANCE TRUST
     $400,000,000 CLASS A-2 FLOATING RATE ASSET-BACKED NOTES, SERIES 1999-1
                                  SUBCLASS A-2

No. ___
                                                                          CUSIP:
                                                                           ISIN:
                                                                    COMMON CODE:

$_________________

         AIRCRAFT FINANCE TRUST, a business trust organized under the
laws of the State of Delaware  (herein  referred to as the "Issuer"),  for value
received,  hereby  promises to pay to CEDE & CO.,  or  registered  assigns,  the
principal sum of __________  DOLLARS  ($___________) on May 15, 2024 (the "Final
Maturity  Date") and to pay  interest  monthly  in  arrears  on the  Outstanding
Principal  Balance hereof at a fluctuating  interest rate per annum equal to the
sum of LIBOR (calculated as provided in the Indenture) plus 0.50% per annum (the
"Stated Rate of Interest") from the date hereof until the Outstanding  Principal
Balance hereof is paid,  payable on each Payment Date.  Interest on the Subclass
A-2  Notes  in  each  Interest   Accrual   Period  will  be  calculated  by  the
Administrative  Agent (as hereinafter defined) by multiplying the Stated Rate of
Interest on the Subclass A-2 Notes for the relevant  Interest  Accrual Period by
the Outstanding  Principal Balance of the Subclass A-2 Notes on the first day of
such Interest Accrual Period and by multiplying the product by the actual number
of days  in such  Interest  Accrual  Period  divided  by 360  and  rounding  the
resulting amount to the nearest cent (with half a cent being rounded upwards).

         This  Subclass A-2 Note is one of a duly  authorized  issue of Notes of
the Issuer issued under the Trust  Indenture dated as of May 5, 1999 (as amended
or  supplemented  from  time to time,  the  "Indenture"),  between  the  Issuer,
ReSource/Phoenix,   Inc.,   in  its  capacity  as   Administrative   Agent  (the

<PAGE>

"Administrative  Agent") and Bankers Trust Company,  as trustee (the "Trustee").
The  Indenture  also  provides for the issuance of Class A Notes of any subclass
(including  additional  Subclass  A-2 Notes),  Class B Notes,  Class C Notes and
Class D Notes.  All  capitalized  terms used in this  Subclass  A-2 Note and not
defined herein shall have the respective  meanings assigned to such terms in the
Indenture.  Reference is made to the Indenture and all  indentures  supplemental
thereto for a statement of the respective  rights and obligations  thereunder of
the Issuer, the Trustee and the Subclass A-2 Holders.  This Subclass A-2 Note is
subject to all of the terms of the Indenture.

         The  Outstanding  Principal  Balance of this  Subclass  A-2 Note may be
repaid prior to the Final  Maturity Date through the  application on the Payment
Dates of the  Available  Collections  to the  principal  hereof as  provided  in
Section 3.08 of the Indenture (after making payments  entitled to priority under
Section 3.08 of the Indenture).  In addition,  the Issuer may optionally  redeem
all or part of the  Outstanding  Principal  Balance of this Subclass A-2 Note on
any Payment Date at the applicable  Redemption Price  (calculated as provided in
the Indenture) or, in the case of a redemption for taxation reasons specified in
the Indenture or a redemption in certain  default  circumstances  as provided in
the  Indenture,  at the  Outstanding  Principal  Balance hereof plus accrued and
unpaid interest hereon.

         Any amount of premium or interest on this Subclass A-2 Note that is not
paid when due shall,  to the fullest  extent  permitted by applicable  law, bear
interest at an interest rate per annum equal to the Stated Rate of Interest from
the date when due until such amount is paid or duly provided for, payable on the
next  succeeding  Payment  Date,  subject to the  availability  of the Available
Collections  therefor after making  payments  entitled to priority under Section
3.08 of the Indenture.

<PAGE>

         The indebtedness  evidenced by the Subclass A-2 Notes is, to the extent
and in the manner  provided in the Indenture and the Security  Trust  Agreement,
subordinate  and subject in right of payment to the prior payment in full of all
Senior  Claims (as  defined in the  Indenture),  and this  Subclass  A-2 Note is
issued subject to the provisions thereof providing for such subordination.  Each
Holder of this Subclass A-2 Note, by accepting the same, (a) agrees to and shall
be bound by such  provisions,  (b)  authorizes  and  directs the Trustee and the
Security  Trustee  on its  behalf to take such  action  as may be  necessary  or
appropriate to effectuate the subordination as provided in the Indenture and (c)
appoints each of the Trustee and the Security Trustee its  attorney-in-fact  for
such  purpose.  All  payments  or  distributions  upon  or with  respect  to any
Obligations (as defined in the  Indenture),  which include payment of principal,
premium and interest on this Note,  that are received by the Holder of this Note
contrary to the priority of payment  provisions of the Indenture or in excess of
the amounts to which the Holder of this Note is entitled  under  Section 3.08 of
the  Indenture  shall be  received  for the benefit of the Senior  Claimant  (as
defined in the  Indenture),  shall be  segregated  from other funds and property
held by the Holder of this Note and shall be forthwith paid over to the Security
Trustee in the same form as so received (with any necessary  endorsement)  to be
applied (in the case of cash) to or held as collateral  (in the case of non-cash
property or  securities)  for the payment or prepayment of the Senior Claims (as
defined in the Indenture) in accordance with the terms of the Indenture.

         The maturity of this Subclass A-2 Note is subject to acceleration  upon
the occurrence and during the continuance of the Events of Default  specified in
the Indenture.

         This Subclass A-2 Note is and will be secured,  on a subordinated basis
as referred to above, by the collateral pledged as security therefor as provided
in the Security Trust Agreement.

<PAGE>

         Subject to and in  accordance  with the terms of the  Indenture,  there
will be distributed monthly on each Payment Date commencing on June 15, 1999, to
the Person in whose name this  Subclass A-2 Note is  registered  at the close of
business on the Record Date with respect to such Payment Date, such Person's pro
rata share  (based on the  aggregate  percentage  of the  Outstanding  Principal
Balance of the Subclass A-2 Notes held by such Person) of the  aggregate  amount
as may be  distributable  to all Holders of Subclass  A-2 Notes on such  Payment
Date pursuant to Section 3.08 of the Indenture.

         UNLESS THIS NOTE IS PRESENTED BY AN  AUTHORIZED  REPRESENTATIVE  OF THE
         DEPOSITORY  TRUST  COMPANY TO AIRCRAFT  FINANCE  TRUST OR ITS AGENT FOR
         REGISTRATION OF TRANSFER,  EXCHANGE OR PAYMENT,  AND ANY NOTE ISSUED IS
         REGISTERED  IN THE NAME OF CEDE & CO.  OR TO SUCH  OTHER  ENTITY  AS IS
         REQUESTED  BY AN  AUTHORIZED  REPRESENTATIVE  OF THE  DEPOSITORY  TRUST
         COMPANY (AND ANY PAYMENT  HEREON IS MADE TO CEDE & CO. OR TO SUCH OTHER
         ENTITY  AS  IS  REQUESTED  BY  AN  AUTHORIZED   REPRESENTATIVE  OF  THE
         DEPOSITORY TRUST COMPANY), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR
         VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED
         OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

         TRANSFERS  OF THIS GLOBAL NOTE SHALL BE LIMITED TO  TRANSFERS IN WHOLE,
         BUT NOT IN PART, TO NOMINEES OF CEDE & CO. OR TO A SUCCESSOR THEREOF OR
         SUCH SUCCESSOR'S  NOMINEE AND TRANSFERS OF PORTIONS OF THIS GLOBAL NOTE
         SHALL BE LIMITED TO TRANSFERS MADE IN ACCORDANCE WITH THE  RESTRICTIONS
         SET FORTH IN SECTION 2.13 OF THE INDENTURE.

         All  amounts  payable  in respect  of this  Subclass  A-2 Note shall be
payable in U.S. dollars in immediately available funds in the manner provided in
the  Indenture to the Holder hereof on the Record Date relating to such payment.
The final payment with respect to this Subclass A-2 Note, however, shall be made
only upon  presentation and surrender of this Note by the Holder or its agent at
the Corporate Trust Office or agency of the Trustee or Paying Agent specified in
the  notice  given by the  Trustee or Paying  Agent  with  respect to such final
payment. The Trustee or Paying Agent shall mail such notice of the final payment

<PAGE>

of this  Note to the  Holder,  specifying  the date  and  amount  of such  final
payment,  no later than five Business Days prior to such final payment.  At such
time,  if any,  as this  Subclass  A-2 Note is issued in the form of one or more
Definitive  Notes,  payments on a Payment  Date shall be made by check mailed to
each  Holder of such a  Definitive  Note on the  applicable  Record  Date at its
address appearing on the Register maintained with respect to Subclass A-2 Notes.
Alternatively,  upon  application in writing to the Trustee,  not later than the
applicable  Record Date, by a Holder of one or more Definitive Notes of Subclass
A-2 Notes having an aggregate principal amount of not less than $1,000,000,  any
such payments  shall be made by wire  transfer to an account  designated by such
Holder at a financial  institution in New York, New York. The final payment with
respect  to  any  such  Definitive  Note,  however,  shall  be  made  only  upon
presentation and surrender of such Definitive Note by the Holder or its agent at
the Corporate Trust Office or agency of the Trustee or Paying Agent specified in
the notice of such final  payment  given by the  Trustee  or Paying  Agent.  The
Trustee or Paying Agent shall mail such notice of the final payment of this Note
to the Holder,  specifying the date and amount of such final  payment,  no later
than five Business Days prior to such final payment.

                  This Subclass A-2 Note is issuable only in registered  form. A
Holder may  transfer  this Note only by  written  application  to the  Registrar
stating the name of the proposed  transferee  and otherwise  complying  with the
terms of the  Indenture.  No such transfer  shall be effective  until,  and such
transferee shall succeed to the rights of a Holder only upon, final registration
of the transfer by the Registrar in the Register. When this Subclass A-2 Note is
presented  to the  Registrar  with a request  to  register  the  transfer  or to
exchange  it for an  equal  principal  amount  of  Subclass  A-2  Notes of other
authorized denominations (including an exchange of this Subclass A-2 Note for an
Exchange  Note),  the Registrar shall register the transfer or make the exchange

<PAGE>

as requested if its  requirements for such  transactions are met (including,  in
the case of a  transfer,  that such Note is duly  endorsed or  accompanied  by a
written instrument of transfer in form satisfactory to the Trustee and Registrar
duly  executed by the Holder  thereof or by an  attorney  who is  authorized  in
writing to act on behalf of the Holder). No service charge shall be made for any
registration  of transfer or exchange of this  Subclass A-2 Note,  but the party
requesting  such new Note or Notes may be  required to pay a sum  sufficient  to
cover any  transfer tax or similar  governmental  charge  payable in  connection
therewith.

         Prior to the  registration  of transfer of this Subclass A-2 Note,  the
Issuer and the Trustee may deem and treat the Person in whose name this Subclass
A-2  Note (as of the day of  determination  or as of such  other  date as may be
specified in the  Indenture)  is  registered  as the  absolute  owner and Holder
hereof for the purpose of receiving  payment of all amounts payable with respect
to this Subclass A-2 Note and for all other purposes, and neither the Issuer nor
the Trustee shall be affected by notice to the contrary.

         The Indenture  permits the amendment or  modification  of the Indenture
and the  Subclass  A-2 Notes by the issuer  with the consent of the Holders of a
majority of the  Outstanding  Principal  Balance of all Notes on the date of any
vote of such Holders (voting as a single class);  provided that, (A) without the
consent of each provider of a Credit Facility,  no such amendment may modify (i)
the  provisions of the Indenture  relating to such Person's  Credit  Facility or
(ii) to the extent  affecting such Person's Credit Facility,  Credit  Facilities
generally; provided further that, (B) without the consent of each Swap Provider,
each  provider  of a Credit  Facility  and each  Holder  of any  Notes,  in each
instance affected thereby,  no such amendment may, except as otherwise  provided
in Section 3.11 of the Indenture,  (i) modify the provisions of the Indenture or
the Notes  setting  forth the  frequency  or the  currency  of  payment  of, the

<PAGE>

maturity  of, or the method of  calculation  of the  amount  of,  any  interest,
principal or Redemption  Price and Sale Premium,  if any,  payable in respect of
any subclass of Notes,  (ii) reduce the percentage of the aggregate  Outstanding
Principal  Balance of any subclass of Notes required to approve any amendment or
waiver of Section 9.01 of the  Indenture  or,  except as  otherwise  provided in
Section 3.09 of the Indenture,  (iii) alter the manner or priority of payment of
such subclass of Notes (each such amendment referred to in subsection A and B, a
"Basic Terms  Modification").  The  Indenture  also permits the Trustee to agree
with the  Issuer,  without  the  consent of any Holder of the Notes,  (a) to any
modification  (other  than a Basic  Terms  Modification)  of,  or the  waiver or
authorization  of any breach or  prospective  breach of,  any  provision  of any
Related  Document  or of the  relevant  subclass  of Notes to correct a manifest
error or an error which is of a formal, minor or technical nature, (b) to modify
the provisions of the Indenture or the Administrative  Agency Agreement relating
to the  timing of  movement  of Rental  Payments  or other  monies  received  or
Expenses Incurred among the Accounts by the Administrative  Agent, (c) to add or
reflect  any Credit  Facility,  (d) to any  amendment  (other than a Basic Terms
Modification)  of an  immaterial  nature  necessary  to permit the  issuance  of
Refinancing  Notes and/or  Additional  Notes and the  acquisition  of Additional
Aircraft  consistent  with the expense  provisions  of the  Indenture  or (e) to
comply  with  the   requirements  of  the  Commission  in  connection  with  the
qualification  of the  Indenture  under  the  Trust  Indenture  Act of 1939  (as
amended,  the "Trust  Indenture  Act").  Any  amendment or  modification  of the
Indenture  shall be  binding on every  Holder  hereof,  whether or not  notation
thereof is made upon this Subclass A-2 Note.

         The subordination  provisions  contained in Section 3.08,  Section 3.09
and  Article X of the  Indenture  may not be amended  or  modified  without  the
consent of each Swap Provider,  each provider of a Credit Facility,  each Holder

<PAGE>

of the Notes of the subclass affected thereby and each Holder of any subclass of
Notes ranking  senior  thereto.  In no event shall the  provisions  set forth in
Section 3.08 of the  Indenture  relating to the priority of the  Expenses,  Swap
Payments and payments under all Credit Facilities be amended or modified.

         The Indenture also contains provisions  permitting the Holders of Notes
representing  a  majority  of the  Outstanding  Principal  Balance of the Senior
Class,  on behalf of the  Holders of all of the  Subclass  A-2  Notes,  to waive
compliance  by the Issuer with certain  provisions  of the Indenture and certain
past defaults  under the Indenture and their  consequences.  Any such consent or
waiver shall be  conclusive  and binding upon all present and future  Holders of
this Subclass A-2 Note and of any Subclass A-2 Note issued upon the registration
of  transfer  of,  in  exchange  or in lieu of or upon the  refinancing  of this
Subclass  A-2 Note,  whether or not  notation of such  consent or waiver is made
upon this Subclass A-2 Note.

         The  term  "Issuer"  as used in this  Subclass  A-2 Note  includes  any
successor to the Issuer under the Indenture.

         The Issuer is permitted by the Indenture,  under certain circumstances,
to merge or consolidate, subject to the rights of the Trustee and the Holders of
Subclass A-2 Notes under the Indenture.

         The  Subclass  A-2  Notes  are  issuable  only  in  registered  form in
denominations  as  provided  in the  Indenture,  subject to certain  limitations
therein set forth.

         THIS  SUBCLASS  A-2 NOTE  SHALL IN ALL  RESPECTS  BE  GOVERNED  BY, AND
CONSTRUED IN ACCORDANCE  WITH, THE LAWS OF THE STATE OF NEW YORK,  INCLUDING ALL
MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE.

<PAGE>

         Unless the  certificate of  authentication  hereon has been executed by
the Trustee  whose name  appears  below by manual or facsimile  signature,  this
Subclass A-2 Note shall not be entitled to any benefit under the  Indenture,  or
be valid or obligatory for any purpose.

<PAGE>

         IN WITNESS WHEREOF,  the Issuer has caused this Subclass A-2 Note to be
signed manually or by facsimile by its Owner Trustee.

Date: _________________                     AIRCRAFT FINANCE TRUST
                                            By:     Wilmington Trust Company,
                                            not in its individual capacity but
                                            solely as the Owner Trustee

                                            By:_________________________________
                                                 Name:
                                                 Title:  Authorized Signatory

<PAGE>

                     TRUSTEE'S CERTIFICATE OF AUTHENTICATION

         This is one of the Subclass A-2 Notes  designated above and referred to
in the within-mentioned Indenture.

Date: ____________                 BANKERS TRUST COMPANY, not in its individual
                                      capacity but solely as the Trustee

                                   By: _______________________________
                                            Authorized Signatory

<PAGE>

                                 TRANSFER NOTICE

         FOR VALUE RECEIVED the  undersigned  registered  holder hereby sell(s),
assign(s) and transfer(s) unto

Insert Taxpayer Identification No. __________________

________________________________________________________________________________
(Please print or typewrite name and address including zip code of assignee)

the within Note and all rights thereunder, hereby irrevocably constituting and
appointing  ______________________________ attorney to transfer said Note on the
books of the Issuer with full power of substitution in the premises.

Date:                                       {Signature of Transferor}
                                            NOTE:    The   signature   to   this
                                            assignment  must correspond with the
                                            name as written upon the face of the
                                            within-mentioned instrument in every
                                            particular,  without  alteration  or
                                            any change whatsoever.

         The  undersigned  covenants  and agrees that it will treat this Note as
indebtedness  for all  purposes  and will not take any action  contrary  to such
characterization,  including,  without  limitation,  filing  any tax  returns or
financial statements inconsistent therewith.

Date:                                       {Signature of Transferee}
                                            NOTICE:  to be executed by an
                                            executive officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00004-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00004-of-00352.parquet"}]]